Skip to content
- Merck says experimental RSV treatment protected infants during the trial, paving the way for possible approvalCNBC
- Merck’s posts more positive Clesrovimab RSV candidate study dataMarketWatch
- Merck’s Clesrovimab (MK-1654), a preventive respiratory syncytial virus (RSV) monoclonal antibody, significantly reduces the incidence of RSV disease and hospitalizations in healthy preterm and full-term infantsYahoo Finance
- IDWeek: Clesrovimab reduces RSV disease and hospitalization in healthy infantsContemporary pediatrics
- Merck’s RSV antibody for infants shows greater than 60% efficacy in a mid-late phase studyReuters.com
